| Tissue-specific immunopathology in fatal COVID-19 DA Dorward, CD Russell, IH Um, M Elshani, SD Armstrong, ... American journal of respiratory and critical care medicine 203 (2), 192-201, 2021 | 339 | 2021 |
| The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial H Schwenzer, E De Zan, M Elshani, R Van Stiphout, M Kudsy, J Morris, ... Clinical Cancer Research 27 (23), 6500-6513, 2021 | 33 | 2021 |
| Podocyte injury elicits loss and recovery of cellular forces KE Haley, NM Kronenberg, P Liehm, M Elshani, C Bell, DJ Harrison, ... Science Advances 4 (6), eaap8030, 2018 | 22 | 2018 |
| Spatial analysis of nqo1 in non-small cell lung cancer shows its expression is independent of nrf1 and nrf2 in the tumor microenvironment B Kaghazchi, IH Um, M Elshani, OJ Read, DJ Harrison Biomolecules 12 (11), 1652, 2022 | 8 | 2022 |
| YAP translocation precedes cytoskeletal rearrangement in podocyte stress response: a podometric investigation of diabetic nephropathy KE Haley, M Elshani, IH Um, C Bell, PD Caie, DJ Harrison, PA Reynolds Frontiers in Physiology 12, 625762, 2021 | 4 | 2021 |
| From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738 H Schwenzer, M Serpi, V Ferrari, J Chettle, J Morris, R van Stiphout, ... Cancer Research 81 (13_Supplement), 931-931, 2021 | 2 | 2021 |
| Transcription factor NFE2L1 decreases in glomerulonephropathies after podocyte damage M Elshani, IH Um, S Leung, PA Reynolds, A Chapman, M Kudsy, ... Cells 12 (17), 2165, 2023 | 1 | 2023 |
| NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells AM Shahid, IH Um, M Elshani, Y Zhang, DJ Harrison Plos one 17 (12), e0278209, 2022 | 1 | 2022 |
| Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy AL Dickson, GM Zickuhr, IH Um, Y Zhang, R Plummer, SP Blagden, ... Cancer Research 84 (6_Supplement), 6222-6222, 2024 | | 2024 |
| RNA regulatory disruption by 3’-dATP: A novel approach to inhibit ribosome biogenesis in cancer M Elshani, Y Zhang, IH Um, R Plummer, SP Blagden, SN Symeonides, ... Cancer Research 84 (6_Supplement), 5650-5650, 2024 | | 2024 |
| Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide: 701 study SP Blagden, SN Symeonides, A Skolariki, NM Haris, Z Boh, IH Um, ... Molecular Cancer Therapeutics 22 (12_Supplement), C032-C032, 2023 | | 2023 |
| NUC-7738 promotes alternative polyadenylation site usage and reduces glutaminase GAC isoform M Elshani, Y Zhang, T Hawkins, M Kudsy, IH Um, G Zickuhr, AL Dickson, ... Cancer Research 83 (7_Supplement), 277-277, 2023 | | 2023 |
| NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients M Elshani, Y Zhang, B Kaghazchi, AL Dickson, SP Blagden, ... Cancer Research 83 (7_Supplement), 5962-5962, 2023 | | 2023 |
| P459: NUC-7738 REGULATES BETA-CATENIN SIGNALLING RESULTING IN REDUCED PROLIFERATION AND SELF-RENEWAL OF AML CELLS AM Shahid, M Elshani, DJ Harrison HemaSphere 6, 358-359, 2022 | | 2022 |
| Tissue-specific tolerance in fatal Covid-19 (preprint) DA Dorward, CD Russell, IH Um, M Elshani, SD Armstrong, ... | | 2020 |
| Abstract C122: NUC-7738, a novel ProTide modification of 3’-deoxyadenosine, activates AMPK and kills renal cancer cells in vitro M Kudsy, M Elshani, S Puthur, IH Um, GD Stewart, M Rahilly, A Chapman, ... Molecular Cancer Therapeutics 18 (12_Supplement), C122-C122, 2019 | | 2019 |
David J HarrisonUniversity of St AndrewsVerified email at nucana.com
